KOVE Medical Raises CHF 1.6M Seed to Advance Fetal Surgery Device

KOVE Medical Secures CHF 1.6M Seed Funding

Zurich-based medtech startup KOVE Medical has raised CHF 1.6 million in a Seed round, according to a recent filing. The company, spun out of the University of Zurich and University Hospital Zurich, is developing an implantable device designed to seal the uterine membrane puncture created during fetal surgery, with the goal of reducing the risk of preterm birth.

Founded in 2020, KOVE Medical is progressing its device toward First-in-Human studies. The funding will support these efforts, though specific use of proceeds was not disclosed.

About KOVE Medical

KOVE Medical focuses on addressing a critical complication in fetal surgery: the puncture in the uterine membrane that can lead to preterm birth. By sealing this puncture, the device aims to improve outcomes for both mother and fetus.

The company's technology originates from academic research at the University of Zurich and University Hospital Zurich, positioning it at the intersection of clinical need and scientific innovation.

Funding Details

The Seed round was completed on August 31, 2026. The company did not disclose the lead investor or a list of participating investors in the announcement.

As KOVE Medical moves toward First-in-Human studies, the new capital is expected to accelerate development milestones. The company's progress will be closely watched by the medtech community, given the potential impact on fetal surgery safety.